Target Price | $76.50 |
Price | $74.82 |
Potential |
2.25%
register free of charge
|
Number of Estimates | 11 |
11 Analysts have issued a price target Halozyme Therapeutics, Inc. 2026 .
The average Halozyme Therapeutics, Inc. target price is $76.50.
This is
2.25%
register free of charge
$95.55
27.71%
register free of charge
$51.51
31.15%
register free of charge
|
|
A rating was issued by 16 analysts: 11 Analysts recommend Halozyme Therapeutics, Inc. to buy, 4 to hold and 1 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the Halozyme Therapeutics, Inc. stock has an average upside potential 2026 of
2.25%
register free of charge
|
Dec '24 |
2025 Estimates |
|
---|---|---|
Revenue Billion $ | 1.02 | 1.35 |
22.44% | 32.57% | |
EBITDA Margin | 61.31% | 61.14% |
23.60% | 0.28% | |
Net Margin | 43.74% | 54.69% |
28.81% | 25.04% |
11 Analysts have issued a sales forecast Halozyme Therapeutics, Inc. 2025 . The average Halozyme Therapeutics, Inc. sales estimate is
This results in the following potential growth metrics:
8 Analysts have issued an Halozyme Therapeutics, Inc. EBITDA forecast 2025. The average Halozyme Therapeutics, Inc. EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
11 Halozyme Therapeutics, Inc. Analysts have issued a net profit forecast 2025. The average Halozyme Therapeutics, Inc. net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Dec '24 |
2025 Estimates |
|
---|---|---|
Earnings Per Share $ | 3.43 | 6.26 |
63.33% | 82.51% | |
P/E | 11.95 | |
EV/Sales | 7.22 |
11 Analysts have issued a Halozyme Therapeutics, Inc. forecast for earnings per share. The average Halozyme Therapeutics, Inc. EPS is
This results in the following potential growth metrics and future valuations:
Halozyme Therapeutics, Inc....
Analyst | Rating | Action | Date |
---|---|---|---|
Morgan Stanley |
Locked
➜
Locked
|
Locked | Aug 18 2025 |
JP Morgan |
Locked
➜
Locked
|
Locked | Aug 07 2025 |
HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Aug 06 2025 |
JMP Securities |
Locked
➜
Locked
|
Locked | Aug 06 2025 |
Morgan Stanley |
Locked
➜
Locked
|
Locked | Aug 06 2025 |
JP Morgan |
Locked
➜
Locked
|
Locked | Jul 16 2025 |
HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | May 29 2025 |
Analyst Rating | Date |
---|---|
Locked
Morgan Stanley:
Locked
➜
Locked
|
Aug 18 2025 |
Locked
JP Morgan:
Locked
➜
Locked
|
Aug 07 2025 |
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Aug 06 2025 |
Locked
JMP Securities:
Locked
➜
Locked
|
Aug 06 2025 |
Locked
Morgan Stanley:
Locked
➜
Locked
|
Aug 06 2025 |
Locked
JP Morgan:
Locked
➜
Locked
|
Jul 16 2025 |
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
May 29 2025 |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.